B-cell Maturation Antigen (BCMA) Targeted Therapies Market Demand Escalating on Growing Popularity To 2026 Global Key Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., and Autolus Ltd.

Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a crucial part of the immune system, which helps to fight against various types of infections and several other diseases. Multiple myeloma is a type of cancer formed by malignant plasma cells and characterized by low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia. Also, multiple myeloma remains as an incurable disease. According to the American Cancer Society, in 2017, an estimated 30,280 a­­­­­dults (17,490 men and 12,790 women) in the U.S. will be diagnosed with multiple myeloma and 12,590 deaths (6,660 men and 5,930 women) will occur in U.S. in 2017 due to multiple myeloma disease. According to the National Center for Biotechnology Information 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

Download PDF Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/190

Market Dynamics:

Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Market Taxonomy:

This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma. For comprehensive understanding of market dynamics, the global B-cell Maturation Antigen (BCMA) targeted therapies market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market:

Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/190

Detailed Segmentation:

Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type:
Antibody Drug Conjugates
CAR-T Cells
Bispecific Antibodies

Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication:
Acute Lymphoblastic Leukemia
Multiple Myeloma

Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.